Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David M Burger

Showing results (211-220 of 337) with videos related to

Pageof 34
Sort By:
Tropical Medicine & International Health : TM & IH|April 30, 2005
Evaluation of antiretroviral therapy results in a resource-poor setting in Blantyre, MalawiJoep J van Oosterhout, Neena Bodasing, Johnstone J Kumwenda, et al.
Expert Review of Clinical Pharmacology|February 10, 2026
Evaluation of drug-drug interactions associated with metamizole in clinical practiceTom G Jacobs, Sharon E J D van den Eijnde, Laura Nijboer, et al.
Clinical Pharmacology and Therapeutics|February 2, 2002
The influence of efavirenz on the pharmacokinetics of a twice-daily combination of indinavir and low-dose ritonavir in healthy volunteersRob E Aarnoutse, Karin J T Grintjes, Denise S C Telgt, et al.
Antiviral Therapy|May 12, 2004
Safety and efficacy of a NRTI-sparing HAART regimen of efavirenz and lopinavir/ritonavir in HIV-1-infected childrenPieter L A Fraaij, Jennifer Neubert, Alina S Bergshoeff, et al.
Pharmaceutics|May 27, 2023
Lamivudine and Emtricitabine Dosing Proposal for Children with HIV and Chronic Kidney Disease, Supported by Physiologically Based Pharmacokinetic ModellingTom G Jacobs, Marika A de Hoop-Sommen, Thomas Nieuwenstein, et al.
The Lancet. Oncology|April 4, 2019
Dose recommendations for anticancer drugs in patients with renal or hepatic impairmentStefanie D Krens, Gerben Lassche, Frank G A Jansman, et al.
Antiviral Therapy|March 19, 2013
Prevalence and determinants of virological failure in HIV-infected children on antiretroviral therapy in rural Cameroon: a cross-sectional studyAlexander Zoufaly, Quirine Fillekes, Raffaela Hammerl, et al.
The Lancet. Oncology|June 5, 2019
Use of the Child-Pugh score in anticancer drug dosing decision making: proceed with caution - Authors' replyStefanie D Krens, Gerben Lassche, Frank G A Jansman, et al.
British Journal of Clinical Pharmacology|January 13, 2017
Dose evaluation of lamivudine in human immunodeficiency virus-infected children aged 5 months to 18 years based on a population pharmacokinetic analysisEsther J H Janssen, Diane E T Bastiaans, Pyry A J Välitalo, et al.
AIDS (London, England)|May 6, 2008
High incidence of adverse events in healthy volunteers receiving rifampicin and adjusted doses of lopinavir/ritonavir tabletsHanneke M J Nijland, Rafaëlla F A L'homme, Gerard A Rongen, et al.
Pageof 34

Showing results (211-220 of 337) with videos related to

Sort By:
Pageof 34
Tropical Medicine & International Health : TM & IH|April 30, 2005
Evaluation of antiretroviral therapy results in a resource-poor setting in Blantyre, MalawiJoep J van Oosterhout, Neena Bodasing, Johnstone J Kumwenda, et al.
Expert Review of Clinical Pharmacology|February 10, 2026
Evaluation of drug-drug interactions associated with metamizole in clinical practiceTom G Jacobs, Sharon E J D van den Eijnde, Laura Nijboer, et al.
Clinical Pharmacology and Therapeutics|February 2, 2002
The influence of efavirenz on the pharmacokinetics of a twice-daily combination of indinavir and low-dose ritonavir in healthy volunteersRob E Aarnoutse, Karin J T Grintjes, Denise S C Telgt, et al.
Antiviral Therapy|May 12, 2004
Safety and efficacy of a NRTI-sparing HAART regimen of efavirenz and lopinavir/ritonavir in HIV-1-infected childrenPieter L A Fraaij, Jennifer Neubert, Alina S Bergshoeff, et al.
Pharmaceutics|May 27, 2023
Lamivudine and Emtricitabine Dosing Proposal for Children with HIV and Chronic Kidney Disease, Supported by Physiologically Based Pharmacokinetic ModellingTom G Jacobs, Marika A de Hoop-Sommen, Thomas Nieuwenstein, et al.
The Lancet. Oncology|April 4, 2019
Dose recommendations for anticancer drugs in patients with renal or hepatic impairmentStefanie D Krens, Gerben Lassche, Frank G A Jansman, et al.
Antiviral Therapy|March 19, 2013
Prevalence and determinants of virological failure in HIV-infected children on antiretroviral therapy in rural Cameroon: a cross-sectional studyAlexander Zoufaly, Quirine Fillekes, Raffaela Hammerl, et al.
The Lancet. Oncology|June 5, 2019
Use of the Child-Pugh score in anticancer drug dosing decision making: proceed with caution - Authors' replyStefanie D Krens, Gerben Lassche, Frank G A Jansman, et al.
British Journal of Clinical Pharmacology|January 13, 2017
Dose evaluation of lamivudine in human immunodeficiency virus-infected children aged 5 months to 18 years based on a population pharmacokinetic analysisEsther J H Janssen, Diane E T Bastiaans, Pyry A J Välitalo, et al.
AIDS (London, England)|May 6, 2008
High incidence of adverse events in healthy volunteers receiving rifampicin and adjusted doses of lopinavir/ritonavir tabletsHanneke M J Nijland, Rafaëlla F A L'homme, Gerard A Rongen, et al.
Pageof 34